Your browser doesn't support javascript.
loading
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321).
Tintelnot, Joseph; Stein, Alexander; Al-Batran, Salah-Eddin; Ettrich, Thomas; Götze, Thorsten; Grün, Barbara; Haag, Georg Martin; Heuer, Vera; Hofheinz, Ralf-Dieter; Homann, Nils; Bröring, Tobias Sebastian; Cruz, Mariana Santos; Kurreck, Annika; Lorenzen, Sylvie; Moosmann, Nicolas; Müller, Christian; Schuler, Markus; Siegler, Gabriele; Binder, Mascha; Gökkurt, Eray.
Afiliação
  • Tintelnot J; ll. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Stein A; Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany.
  • Al-Batran SE; Institute of Clinical Cancer Research, Krankenhaus Nordwest, Frankfurt, Germany.
  • Ettrich T; l. Department of Medicine, University Hospital Ulm, Ulm, Germany.
  • Götze T; Institute of Clinical Cancer Research, Krankenhaus Nordwest, Frankfurt, Germany.
  • Grün B; Department of Medical Oncology, University Medical Center Heidelberg, Heidelberg, Germany.
  • Haag GM; Department of Medical Oncology, University Medical Center Heidelberg, Heidelberg, Germany.
  • Heuer V; Department of Oncology, St. Anna Hospital Herne, Herne, Germany.
  • Hofheinz RD; Medical Department, University Medical Center Mannheim, Mannheim, Germany.
  • Homann N; ll. Medical Department, Klinikum Wolfsburg, Wolfsburg, Germany.
  • Bröring TS; ll. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Cruz MS; ll. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Kurreck A; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany.
  • Lorenzen S; Rechts der Isar Hospital, Technical University of Munich, Munich, Germany.
  • Moosmann N; Department of Oncology and Hematology, Barmherzige Brüder Regensburg Hospital, Regensburg, Germany.
  • Müller C; Department of Hematology and Oncology, Klinik Essen-Mitte, Essen, Germany.
  • Schuler M; Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany.
  • Siegler G; Department of Internal Medicine V, Hematology/Oncology, Hospital Nürnberg Nord/Paracelsus Medical University, Nürnberg, Germany.
  • Binder M; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Gökkurt E; Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany.
Front Oncol ; 13: 1272175, 2023.
Article em En | MEDLINE | ID: mdl-37909020
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha